{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.0","upperLimit":"74.8","value":"70.1"},{"groupId":"OG001","lowerLimit":"84.0","upperLimit":"91.1","value":"87.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"Percentage of participants achieving CR or better were reported. CR or better rate was defined as the percentage of participants achieving CR or sCR based on the computerized algorithm, according to IMWG response criteria. IMWG 2011 criteria for CR: Negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas (PCs), and \\<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2 to 4 color flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with h bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"OG000","title":"Velcade Lenalidomide Dexamethasone (VRd)"},{"description":"Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"OG001","title":"Daratumumab + VRd (D-VRd)"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat (ITT) population included all randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the clinical cutoff date. Maximum follow up was 54.41 months","title":"Percentage of Participants With Overall Complete Response (CR) or Better","type":"SECONDARY","unitOfMeasure":"percentage of participants with response"}